{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059381","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.412356+00:00","generated_at":"2026-06-08T21:46:56.650190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%","bullets":["Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.","Roxadustat net product revenue in China reached $29.4M, up 69% YoY; total China sales $77.1M (up 31%), driven by 37% volume growth.","Annualized cost reduction of $120M implemented; cash of $283.0M expected to fund operations into 2026.","Pamrevlumab LAPIS Phase 3 topline data expected Q1 2024; PanCAN Phase 2/3 data in 1H 2024.","sNDA for roxadustat in chemotherapy-induced anemia accepted in China; approval decision mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059381","json":"https://secwatch.observer/filing/0000950170-23-059381.json","markdown":"https://secwatch.observer/filing/0000950170-23-059381.md","text":"https://secwatch.observer/filing/0000950170-23-059381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/0000950170-23-059381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/fgen-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:46:56.650190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8ad870977e50e7550bc4448f03c35ec4a2767e1","claim":"KYNTRA BIO, INC. reported third quarter 2023 results: revenue Total revenue for the third quarter of 2023 was $40.1 million, net income Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, EPS $0.65 net loss per basic and diluted share.","evidence_excerpt":"FibroGen Reports Third Quarter 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023059381/0000950170-23-059381-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"Total revenue for the third quarter of 2023 was $40.1 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share"},{"label":"EPS","value":"$0.65 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}